FGF21 emerges as key next step beyond GLP-1 in obesity and cardiometabolic treatment, with $10.7B in pharma deals.

Novo Nordisk's oral Wegovy boosts obesity market, driving strong sales and raised 2026 guidance with $75 target.

Novo Nordisk is rated a BUY as its oral Wegovy drug rapidly expands the obesity treatment market in the U.S., with over 3 million prescriptions in five months, mostly from patients new to GLP-1 treatments. This strong demand has led management to rai...